Prosecution Insights
Last updated: November 20, 2026

Adam Adrien Germain, USPTO Patent Examiner

Listed by the USPTO as GERMAIN, ADAM ADRIEN

Tech Center 1700 • Art Units: 1718 1772 1776 1777

This examiner grants 39% of resolved cases

Analysis

GERMAIN, ADAM ADRIEN is assigned to Tech Center 1700 and Art Unit 1718. The record covers 64 resolved cases, with a 39.1% allowance rate and a median of 1288 days to allowance. Interviews are associated with a 12.6% lift.

The listed companies are The Brigham and Women's Hospital Inc., Baxter Healthcare S.A., and Xingmai Innovation Technology (Suzhou) Co. Ltd. The listed firms are BrainSpark Associates, LLC, Bridgeway IP Law Group, PLLC, and BUCHANAN INGERSOLL & ROONEY PC. The data supports a measured prosecution approach, with interviews serving as a supplement to written responses in a docket showing mixed allowance outcomes and extended timing.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

39.1%
Allow Rate
-25.9% vs TC avg
116
Total Applications
+12.6%
Interview Lift
1288
Avg Prosecution Days
Based on 64 resolved cases, 2023–2026

Rejection Statute Breakdown

3.8%
§101 Eligibility
14.3%
§102 Novelty
54.8%
§103 Obviousness
26.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18065857 ULTRAPURE WATER SUPPLY APPARATUS, SUBSTRATE PROCESSING SYSTEM INCLUDING THE SAME, AND SUBSTRATE PROCESSING METHOD USING THE SAME Non-Final OA Samsung Electronics Co., Ltd.
17798937 METHODS OF MEASURING AND PURIFYING EXTRACELLULAR VESICLES Final Rejection The Brigham and Women's Hospital, Inc.
19349993 SWIMMING POOL ROBOT Final Rejection XINGMAI INNOVATION TECHNOLOGY (SUZHOU) CO., LTD.
17640868 EVAPORATION MODULE FOR PRODUCING CONCENTRATE, AND LIQUID PRODUCT MANUFACTURING SYSTEM INCLUDING SAME Non-Final OA CJ CHEILJEDANG CORPORATION
17268719 METHOD AND CHROMATOGRAPHY SYSTEM FOR DETERMINING AMOUNT AND PURITY OF A MULTIMERIC PROTEIN Final Rejection REGENERON PHARMACEUTICALS, INC.
18411162 Isolation of Autologous Acellular Biological Therapeutics Non-Final OA GLOBUS MEDICAL, INC.
17758351 COMPOSITE MEMBRANE WITH NANOSELECTIVE SURFACE FOR ORGANIC SOLVENT NANOFILTRATION Non-Final OA W. L. Gore & Associates, Inc.
17937341 LIQUID CHROMATOGRAPH Final Rejection HITACHI HIGH-TECH ANALYSIS CORPORATION
18397353 POLYMER FOR HOLLOW FIBER MEMBRANE FOR ORGANIC SOLVENT NANOFILTRATION AND METHOD FOR MANUFACTURING THE SAME Non-Final OA GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
17912702 WATER TREATMENT METHOD, WATER TREATMENT DEVICE AND SLIME INHIBITOR FOR MEMBRANES Non-Final OA ORGANO CORPORATION
18831109 Non-Final OA Individual inventor

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Adam Adrien Germain's allowance rate?

39.1% of resolved applications examined by Adam Adrien Germain were allowed (64 resolved cases), compared with 36.6% across Art Unit 1718 over the last five years.

Does an interview help with examiner Adam Adrien Germain?

This examiner's interview lift is +12.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Adam Adrien Germain take to allow a patent?

Applications allowed by Adam Adrien Germain took 1,288 days on average from filing to allowance.

Which art unit does examiner Adam Adrien Germain work in?

Adam Adrien Germain examines applications in Art Unit 1718 in Tech Center 1700 (Chemistry & Materials).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month